TLDR
- Gilead stock climbs 2.96% as Hepcludex gets FDA nod for chronic HDV.
- Hepcludex becomes the first FDA-approved U.S. treatment for hepatitis delta.
- Phase 3 data shows Hepcludex reduces HDV RNA and normalizes ALT levels.
- Treatment targets both HDV and HBV, blocking viral entry into liver cells.
- U.S. program aids patient access and ensures monitoring for treatment safety.
Gilead Sciences, Inc. (GILD) shares rose to $134.36, up $3.86 (+2.96%), following FDA approval of Hepcludex®. The approval makes Hepcludex the first U.S. treatment for chronic hepatitis delta virus (HDV) infection. The move reflects a major advancement in addressing a long-standing unmet medical need.
FDA Accelerates Approval for Hepcludex
Hepcludex 8.5 mg received accelerated approval based on reductions in HDV RNA and ALT normalization. The Phase 3 MYR301 study showed a significant combined virologic and biochemical response at Week 48. Patients continued treatment up to 144 weeks, showing sustained efficacy and general tolerability.
Chronic HDV affects roughly 2% to 4% of individuals with hepatitis B in the U.S., representing approximately 40,000–80,000 people. The disease progresses faster than HBV alone, with higher risks of liver failure and mortality. Hepcludex is approved for adults with chronic HDV without cirrhosis or with compensated cirrhosis.
The treatment blocks entry of both HDV and HBV into liver cells, targeting a critical viral lifecycle step. Continued approval depends on verification of clinical benefit in confirmatory trials. The therapy addresses both virologic and biochemical markers rather than established long-term clinical outcomes.
U.S. Access and Safety Measures
Gilead offers the Support Path® Program to assist patients with treatment coverage and financial options. Healthcare providers receive guidance on managing HBV and HDV alongside Hepcludex therapy. The program aims to facilitate access while monitoring patient safety and response.
Important safety information highlights risks of severe hepatitis exacerbation after discontinuation, especially in cirrhotic patients. Hepatic function must be monitored for at least six months post-treatment. Common adverse reactions include injection site reactions, headache, fatigue, abdominal pain, and pruritus.
Dosage is 8.5 mg once daily via subcutaneous injection, continued as long as a response persists. Optimal treatment duration is unknown, but underlying HBV infection must be managed appropriately. Safety data in pregnancy and lactation are limited, requiring careful consideration of maternal and infant health benefits.
Global Context and Implications
Bulevirtide is also approved in the European Economic Area and select international markets. Hepcludex represents a first-in-class entry inhibitor offering a new pathway for HDV treatment worldwide. Its approval may reshape therapeutic approaches for HDV and co-infected HBV patients.
Long-term studies are underway to confirm clinical benefits and track outcomes. Hepcludex provides a new option for a historically underserved patient population. Gilead’s stock performance reflects market recognition of the treatment’s significance in the U.S. pharmaceutical landscape.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
